GlassScriptPhysician profile
Kristina Kramer
NPI 1598714511
$7,136.81
in general payments reported to CMS, 2019-2025
33 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 82% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $431 · 2021: $487 · 2022: $1,054 · 2023: $1,283 · 2024: $1,949 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,639.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,638.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,029.52 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Glaxosmithkline, LLC. | $1,689.53 | 2019-2025 | Trelegy Ellipta, Shingrix, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,552.42 | 2019-2025 | Airsupra, Breztri, Symbicort |
| United Therapeutics Corporation | $380.49 | 2022-2025 | Tyvaso, Tyvaso |
| Genentech USA, INC. | $192.62 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $148.15 | 2019-2020 | |
| Fisher & Paykel Healthcare INC | $137.76 | 2023-2025 | Fisher & Paykel Healthcare |
| Baxter Healthcare | $135.75 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| 180 Medical, INC. | $106.56 | 2019-2022 | |
| Pulmonx Corporation | $96.92 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $82.06 | 2023 | Glassia |
| Insmed, INC. | $66.89 | 2019-2025 | Arikayce |
| Abbvie INC. | $54.69 | 2023-2025 | |
| Advanced Respiratory, INC | $46.25 | 2019 | |
| Blue Earth Diagnostics | $36.24 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karl Storz Endoscopy-America | $33.11 | 2024 | N.A. |
| Actelion Pharmaceuticals US, INC. | $32.63 | 2022 | |
| La Jolla Pharmaceutical Company | $31.33 | 2023 | Giapreza |
| Bayer Healthcare Pharmaceuticals INC. | $27.01 | 2025 | |
| Endo Pharmaceuticals INC. | $25.26 | 2019 | |
| Pfizer INC. | $24.95 | 2021 | |
| Depuy Synthes Sales INC. | $23.66 | 2022 | |
| Mylan Specialty L.P. | $21.49 | 2019 | |
| Abiomed | $20.16 | 2024 | Impella |
| Otsuka America Pharmaceutical, INC. | $19.66 | 2022 | |
| Dendreon Pharmaceuticals LLC | $18.60 | 2019 | |
| Grifols USA, LLC | $17.70 | 2019 | |
| Boston Scientific Corporation | $17.01 | 2023 | Solyx Sis System |
| Resmed Corp | $16.16 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $15.24 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2020 | |
| Merck Sharp & Dohme LLC | $12.59 | 2020 | |
| Apria Healthcare LLC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.